ATOSSA THERAPEUTICS, INC. (ATOS)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Between 2026-06-07 and 2026-09-05, public records show 1 signal for ATOSSA THERAPEUTICS, INC.. Most notable: 2026-06-11: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-05 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-12 | Steinhart Richard I | director | A | 10,000 | 0 | $0 |
| 2026-05-12 | Chen Shu-Chih | director | A | 10,000 | 0 | $0 |
| 2026-05-12 | Remmel H. Lawrence | director | A | 10,000 | 0 | $0 |
| 2026-05-12 | Finn Jonathan | director | A | 10,000 | 0 | $0 |
| 2026-05-12 | Galli Stephen J | director | A | 10,000 | 0 | $0 |
| 2026-05-12 | Cigler Tessa | director | A | 10,000 | 0 | $0 |
| 2026-03-27 | QUAY STEVEN C | director | A | 65,000 | 0 | $0 |
| 2026-03-26 | Daniel Mark James | officer | A | 63,000 | 0 | $0 |
| 2026-01-20 | QUAY STEVEN C | director | A | 331,674 | 0 | $0 |
| 2026-01-20 | QUAY STEVEN C | director | A | 325,203 | 0 | $0 |
| 2025-05-21 | QUAY STEVEN C | director | P | 11,239 | 0.88 | $9,890 |
| 2025-03-26 | Remmel H. Lawrence | director | P | 10,000 | 0.7 | $7,000 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.